Palisade bio announces closing of $4 million private placement priced at-the- market under nasdaq rules

Carlsbad, ca, may 07, 2024 (globe newswire) -- palisade bio, inc.  (nasdaq: pali), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has closed its previously announced private placement with an institutional investor for the purchase of 615,242 shares of common stock (or certain pre-funded warrants in lieu thereof) for gross proceeds of approximately $4 million, before deducting placement agent fees and other offering expenses payable by the company.
PALI Ratings Summary
PALI Quant Ranking